Stockscreener 앱 받기
218.10
1.53%
-3.39
시간 외 거래:
218.10
전일 마감가:
$221.49
열려 있는:
$211
하루 거래량:
1.67M
Relative Volume:
2.37
시가총액:
$13.33B
수익:
$534.57M
순이익/손실:
$-293.67M
주가수익비율:
-43.90
EPS:
-4.968
순현금흐름:
$-187.10M
1주 성능:
+0.33%
1개월 성능:
+4.47%
6개월 성능:
+11.29%
1년 성능:
+72.90%
1일 변동 폭
$211.00
$222.99
1주일 범위
$211.00
$226.40
52주 변동 폭
$124.06
$242.00
Ascendis Pharma A S Adr Stock (ASND) Company Profile
Compare ASND vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S Adr
|
218.10 | 13.53B | 534.57M | -293.67M | -187.10M | -4.968 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-17 | 개시 | Raymond James | Strong Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-05-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | UBS | Buy |
| 2024-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-06-25 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 개시 | Stifel | Buy |
| 2023-12-20 | 개시 | Jefferies | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Neutral |
| 2023-04-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-04-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-08-30 | 재개 | Berenberg | Buy |
| 2022-03-28 | 재개 | Wedbush | Outperform |
| 2022-03-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-06 | 개시 | Cowen | Market Perform |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-10-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-30 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-11 | 재개 | Stifel | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-10-11 | 개시 | Morgan Stanley | Overweight |
| 2019-03-25 | 개시 | Evercore ISI | Outperform |
| 2019-01-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-01-24 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | 개시 | Stifel | Buy |
| 2018-04-02 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-05-11 | 개시 | JP Morgan | Overweight |
| 2017-03-09 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | 개시 | Credit Suisse | Outperform |
| 2016-09-26 | 개시 | Wedbush | Outperform |
모두보기
Ascendis Pharma A S Adr 주식(ASND)의 최신 뉴스
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Benzinga
Ascendis Pharma (NASDAQ:ASND) Shares Drop After Q4 Earnings Miss on Wider-Than-Expected Loss - Chartmill
Did Health Canada’s Yorvipath Approval Just Shift Ascendis Pharma’s (ASND) Investment Narrative? - Sahm
Assessing Ascendis Pharma (ASND) Valuation After Health Canada Approval For Yorvipath - Sahm
BofA Reiterates Buy Rating on Ascendis Pharma (ASND) While Wells Fargo Analyst Raises PT - Finviz
ASCENDIS PHARMA A/SADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum - Chartmill
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Allstate Upgraded, Amazon Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Is Positive COACH Data and Priority Review for TransCon CNP Reframing Ascendis Pharma’s (ASND) Investment Case? - Sahm
Ascendis Pharma Achondroplasia Data Highlights Emerging Rare Disease Franchise Potential - Sahm
Assessing Ascendis Pharma (ASND) Valuation After Positive COACH Trial Growth And Proportionality Results - Sahm
Ascendis Pharma ADR shows rising price performance with jump to 83 RS rating - MSN
Ascendis Pharma A/S (ASND): A Bull Case Theory - Finviz
Did COACH Trial Combo Data and FDA Priority Review Just Shift Ascendis Pharma's (ASND) Investment Narrative? - Sahm
Ascendis Pharma ADR Shows Rising Price Performance With Jump To 83 RS Rating - Investor's Business Daily
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference - Sahm
Assessing Ascendis Pharma (ASND) Valuation After Positive COACH Phase 2 Achondroplasia Results - Sahm
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) - Sahm
Ascendis Pharma ADR reaches 80-plus relative strength rating benchmark - MSN
Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan - ChartMill
Ascendis Pharma ADR Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Can you now get a good deal on Ascendis Pharma A/S ADR’s shares? - uspostnews.com
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today - Sahm
Ascendis Pharma’s Price Surge Amid New Developments - StocksToTrade
Looking Into Ascendis Pharma AS's Recent Short Interest - Sahm
Taking on analysts’ expectations and winning: Ascendis Pharma A/S ADR (ASND) - setenews.com
Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades' - Sahm
The time has not yet come to remove your chips from the table: Ascendis Pharma A/S ADR (ASND) - setenews.com
Honda Upgraded, McDonald’s Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026 - Sahm
Ascendis Pharma Reports Third Quarter 2025 Financial Results - Sahm
Is the Market Bullish or Bearish on Ascendis Pharma AS? - Sahm
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia - Sahm
Ascendis Pharma ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - MSN
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
ASND | Ascendis Pharma A/S ADR SEC Filings - MarketWatch
European ADRs Slip As Gains And Losses Balance Out - Finimize
Take off with Ascendis Pharma A/S ADR (ASND): Get ready for trading - Setenews
Breakthrough And Pullback | 5 Stocks Deserve Close Attention: ASND, IDCC And More - Sahm
Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Sahm
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? - TradingView
Apple Upgraded, DraftKings Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 81 RS Rating - MSN
New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism - Sahm
Should Positive Three-Year TransCon PTH Data Prompt Action From Ascendis Pharma (ASND) Investors? - Sahm
Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025 - Sahm
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025 - Sahm
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years - Sahm
eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Ascendis Pharma (NasdaqGS:ASND): Evaluating Valuation as Analyst Confidence Rises on Key EMA Filing - Sahm
How Ascendis Pharma’s (ASND) TransCon CNP EMA Submission Has Shaped Its Rare Disease Investment Story - Sahm
Ascendis Pharma A S Adr (ASND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):